472 filings
Page 14 of 24
6-K
3fzzr4t0iwg
6 Feb 20
Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option
6:06am
6-K
13mee5i95s91da 78djr
31 Jan 20
Chi-Med to Announce 2019 Final Results
6:14am
6-K
lctnah57 q48ki0aaa
29 Jan 20
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)I
6:09am
6-K
mq5wr
23 Jan 20
Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs
6:40am
424B5
bvhggs
23 Jan 20
Prospectus supplement for primary offering
6:19am
6-K
1pkeqf
22 Jan 20
Chi-Med Announces Proposed Public Offering of ADSs
6:01am
424B5
zz9kld7
21 Jan 20
Prospectus supplement for primary offering
4:53pm
6-K
6kryczk qvjylf
21 Jan 20
Current report (foreign)
4:19pm
6-K
wzdqj
21 Jan 20
Current report (foreign)
6:19am
CORRESP
8wp 4d0gxix14
15 Jan 20
Correspondence with SEC
12:00am
6-K
urwqd
13 Jan 20
Current report (foreign)
6:19am
6-K
8g84lkw8
6 Jan 20
Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference
6:08am
6-K
tkj0enh
31 Dec 19
Current report (foreign)
6:27am
UPLOAD
3ctv20s17csojc7
31 Dec 19
Letter from SEC
12:00am
6-K
da6o yyo4tbgir9h78f
20 Dec 19
Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China
6:09am
6-K
ovej 8h5hxu3hzbp
12 Dec 19
Current report (foreign)
6:06am
6-K
ojouhoeww9wj
29 Nov 19
Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China
6:12am
6-K
3rep3igh820u xq0zj8
25 Nov 19
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
6:21am
6-K
6vz82
12 Nov 19
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
6:36am
6-K
w060idm
17 Oct 19
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
6:14am